Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks

The S&P 500 dips following the FOMC meeting, but these three biopharmaceutical stocks all soared!

Mar 19, 2014 at 5:15PM

Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 (SNPINDEX:^GSPC) hiccuping and heading lower after the FOMC announced its latest policy decisions.

Longview

According to Yellen, the FOMC will be further tapering its economic stimulus program, known as QE3, which purchases a combination of long-term U.S. Treasuries and mortgage-backed securities by another $10 billion. This marks the third time in a matter of months that the FOMC has tapered QE3 by $10 billion, and the overall monthly allotment is now down to $55 billion. Investors are certainly sad to see this free money disappearing, but it also signals confidence from the Fed that the U.S. economy is able to stand on its own two feet.

In addition, the FOMC updated its views on long-term federal funds target rates, noting that it would no longer view an unemployment rate target of 6.5% as the sole reason to boost rates, but would, instead, take into account a number of factors. This, in turn, gave investors hope that lending rates wouldn't move higher anytime soon.

Also noteworthy, the Mortgage Brokers Association released its weekly mortgage loan origination indicator, which dipped 1.2% from the previous week. Following a nearly two-decade low in December, it's clear that consumers are treading very cautiously despite lending rates that are historically very low. Unless consumers come around to this realization, when rates do begin to tick higher, banks and homebuilders could be in for a very unwelcome shock.

By day's end, investors' disappointment with another taper won out over the prospect of an improving economy, and pushed the S&P 500 lower by 11.48 points (-0.61%) to close at 1,860.77. Despite the drop, a trio of health-care companies led the charge to the upside today.

Topping that list was Prothena (NASDAQ:PRTA), a clinical-stage biopharmaceutical company focused on advancing therapies to treat diseases that involve protein misfolding or cell adhesion. Prothena shares vaulted higher by 27.5% after receiving a price target hike from RBC Capital to $52 from $38, following its own announcement that it would be presenting an abstract of phase 1 clinical data utilizing NEOD001 for patients with immunoglobulin light chain amyloidosis and persistent organ dysfunction at the International Symposium of Amyloidosis. The data in its abstract will include any interim analyses through the end of March. Investors are clearly thinking that Prothena would be unlikely to make this announcement if the data wasn't good, so they're bidding shares notably higher today. I would, however, urge investors to remain cautious, as NEOD001 is Prothena's only clinical-stage therapy, and the company is already valued at a whopping $1 billion.

Shares of polarizing clinical-stage immunotherapy developer Galena Biopharma (NASDAQ:GALE) also roared higher by 9.2% after research firm Maxim Group came to its defense, and noted that its fundamentals are sound despite its ongoing SEC investigation involving its relationship with a third-party according to Barron's. Maxim analyst Echo He noted that a worst-case scenario would involve some liability with management, but wouldn't affect Galena's actual pipeline. He values Galena's FDA-approved breakthrough cancer pain therapy Abstral at $1/share, its cancer immunotherapy NeuVax at $8/share, and Anagrelide CR at $2/share. I believe it's obvious that Galena isn't without a number of clear risks, which include its ongoing SEC investigation, and the fact that small-cap biotechs have a notoriously poor record of late-stage success in developing cancer therapies. Then again, better-than-expected Abstral sales projections and a deep pipeline if NeuVax proves successful does have the opportunity to send this stock higher.

Finally, Horizon Pharma (NASDAQ:HZNP) gained 9.1% after announcing what is effectively a reverse merger with privately held Vidara Therapeutics that amounts to $660 million in cash and stock. The combined entity will be capable of $250 million-$265 million in revenue, with EBITDA in the $65 million-$75 million range. More importantly, the move is being made because it allows Horizon to incorporate in Ireland, which has significantly lower corporate tax rates, allowing it to keep much more of its profits. We saw a similar move from Perrigo (NYSE:PRGO), which agreed to buy Elan for $8.6 billion in July in order to incorporate itself in Ireland and gain the preferential tax treatment in that country. Overall, it appears to be a smart move for Horizon Pharma, and with the company valued at less than 15 times the midpoint of its forecasted EBITDA, I could actually see further upside potential.

Prothena, Galena, and Horizon all shot higher today -- but even they may struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers